Novel approaches in management of perioperative coagulopathy

Current Opinion in Anaesthesiology

Volumn 27, Issue 1, 2014, Pages 72-80

  Tanaka, Kenichi A ^a   Bader, Stephen O ^a   Görlinger, Klaus ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

coagulation; fibrinogen concentrate; monitoring; perioperative hemostasis; thromboelastometry,tranexamic acid

Indexed keywords

FIBRIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; PROTHROMBIN COMPLEX; THROMBIN; TRANEXAMIC ACID;

BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; FIBRIN POLYMERIZATION; FIBRINOGEN DEFECT; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LABORATORY; LABORATORY TEST; PERIOPERATIVE COAGULOPATHY; PRIORITY JOURNAL; REVIEW; SAFETY; VISCOELASTICITY;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; ELASTICITY; FIBRINOGEN; HEMOSTASIS; HUMANS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; PROTHROMBIN; TRANEXAMIC ACID; VISCOSITY;

EID: 84891835014     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000025     Document Type: Review

References (81)

1. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008; 64:S64-S68.
2. Toulon P, Ozier Y, Ankri A, et al. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009; 101:394-401.
3. Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. Transfusion 2010; 50:2547-2552.
4. David JS, Godier A, Dargaud Y, Inaba K. Case scenario: management of trauma-induced coagulopathy in a severe blunt trauma patient. Anesthesiology 2013; 119:191-200.
5. Cross-sectional guidelines for therapy with blood compo nents and plasma derivatives: chapter 7 procoagulators. Transfus Med Hemother 2009; 36:419-436.
6. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944-982.
7. Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531-547.
8. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106:725-731.
9. Lee JW, Yoo YC, Park HK, et al. Fresh frozen plasma in pump priming for congenital heart surgery: evaluation of effects on postoperative coagulation profiles using a fibrinogen assay and rotational thromboelastometry. Yonsei Med J 2013; 54:752-762.
10. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92:178-186.
11. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5:261-269.
12. Rahe-Meyer N, Solomon C, Tokuno ML, et al. Comparative assessment of coagulation changes induced by two different types of heart-lung machine. Artif Organs 2010; 34:3-12.
13. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447-458.
14. Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67:221-227.
15. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management: fresh frozen plasma. Best Pract Res Clin Anaesthesiol 2010; 24:51-64.
16. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792-797.
17. Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth 2012; 26:1083-1093.
18. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106:1366-1375.
19. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26:1-13.
20. Lang T, Bauters A, Braun SL, et al. Multicentre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16:301-310.
21. Coakley M, Reddy K, Mackie I, Mallett S. Transfusion triggers in orthotopic liver transplantation: a comparison of the thromboelastometry analyzer, the thromboelastogram, and conventional coagulation tests. J Cardiothorac Vasc Anesth 2006; 20:548-553.
22. Venema LF, Post WJ, Hendriks HG, et al. An assessment of clinical interchangeability of TEG and RoTEM thromboelastographic variables in cardiac surgical patients. Anesth Analg 2010; 111:339-344.
23. Solomon C, Sorensen B, Hochleitner G, et al. Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry. Anesth Analg 2012; 114:721-730.
24. Larsen OH, Fenger-Eriksen C, Christiansen K, et al. Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents. Anesthesiology 2011; 115:294-302.
25. Scarpelini S, Rhind SG, Nascimento B, et al. Normal range values for thromboelastography in healthy adult volunteers. Braz J Med Biol Res 2009; 42:1210-1217.
26. Haas T, Spielmann N, Mauch J, et al. Comparison of thromboelastometry (ROTEM1) with standard plasmatic coagulation testing in paediatric surgery. Br J Anaesth 2012; 108:36-41.
27. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5:289-295.
28. Roullet S, Pillot J, Freyburger G, et al. Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J Anaesth 2010; 104:422-428.
29. Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilutioninduced coagulation changes after cardiac surgery. Transfusion 2012; 52:14-22.
30. Ogawa S, Szlam F, Bolliger D, et al. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg 2012; 115:16-21.
31. Johansson PI, Stensballe J. Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96:111-118.
32. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100:1781-1785.
33. Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis 2008; 19:106-108.
34. Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102:793-799.
35. Dirkmann D, Gorlinger K, Gisbertz C, et al. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. Anesth Analg 2012; 114:1182-1188.
36. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67:125-131.
37. Ives C, Inaba K, Branco BC, et al. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012; 215:496-502.
38. Cotton BA, Harvin JA, Kostousouv V, et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73:365-370.
39. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebocontrolled clinical trial. J Thromb Haemost 2009; 7:795-802.
40. Gorlinger K, Fries D, Dirkmann D, et al. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus MedHemother 2012; 39:104-113.
41. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118:40-50.
42. Fassl J, Matt P, Eckstein F, et al. Transfusion of allogeneic blood products in proximal aortic surgery with hyopthermic circulatory arrest: Effects of thromboelastometry-guided transfusion management. Journal of Cardiothoracic & Vascular Anesthesia 2013. [Epub ahead of print]. doi: 10.1053/j.jvca.2013. 02.009.
43. RiaSTAP, fibirnogen concentrate (human). CSL Behring, Marburg, Germany: Prescribing Information; 2011.
44. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114:261-274.
45. Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia. Transfus Apher Sci 2012; 46:159-162.
46. Rumph B, Bolliger D, Narang N, et al. In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. J Cardiothorac Vasc Anesth 2010; 24:408-412.
47. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104:555-562.
48. Danes AF, Cuenca LG, Bueno SR, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94: 221-226.
49. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008; 18:151-157.
50. Groner A, Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92:846-849; Haematologica. 2008; 93: e24-6.
51. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834-843.
52. Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009; 20:535-540.
53. Lance MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2012; 103:25-34.
54. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2013. [Epub ahead of print]. doi:10.1111/trf.12248.
55. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastographyguided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312-319.
56. Chowdary P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125:69-73.
57. Tanaka KA, Mazzeffi MA, Grube M, et al. Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion 2013; 53:920-921.
58. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622-631.
59. Kcentra, prothrombin complex concentrate (human). CSL Behring, Marburg, Germany: Prescribing information; 2013.
60. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83:137-143.
61. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331.
62. Aoki N, Saito H, Kamiya T, et al. Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63:877-884.
63. Hvas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5:2408-2414.
64. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth 2013; 111:549-563.
65. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23-32.
66. Ide M, Bolliger D, Taketomi T, Tanaka KA. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth 2010; 24:96-106.
67. Ogawa S, Richardson JE, Sakai T, et al. High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. J Anesth 2012; 26:9-19.
68. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S-325S.
69. Wong J, Abrishami A, El Beheiry H, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010; 92:2503-2513.
70. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002; 97:390-399.
71. Abou-Diwan C, Sniecinski RM, Szlam F, et al. Plasma and cerebral spinal fluid tranexamic acid quantitation in cardiopulmonary bypass patients. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:553-556.
72. de Leede-van der Maarl MG, Hilkens P, Bosch F. The epileptogenic effect of tranexamic acid. J Neurol 1999; 246:843.
73. Yeh HM, Lau HP, Lin PL, et al. Convulsions and refractory ventricular fibrillation after intrathecal injection of a massive dose of tranexamic acid. Anesthesiology 2003; 98:270-272.
74. Garcha PS, Mohan CV, Sharma RM. Death after an inadvertent intrathecal injection of tranexamic acid. Anesth Analg 2007; 104:241-242.
75. Furtmuller R, Schlag MG, Berger M, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301:168-173.
76. Lecker I, Wang DS, Romaschin AD, et al. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122:4654-4666.
77. Gorlinger K, Shore-Lesserson L, Dirkmann D, et al.Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth 2013; 27:S20-S34.
78. Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth 2012; 109:851-863.
79. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109:918-926.
80. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. CRASH-3: tranexamic acid for the treatment of significant traumatic brain injury-study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012; 13:87.
81. Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage-an international randomised, double blind placebo controlled trial. Trials 2010; 11:40.